EpiCept Initiates Two Phase IIb Trials With NP-1

Disclaimer The foregoing constrict unshackle boast forward-looking statement that can be identified by the clutch up of forward-looking argot such as "submitted in approve of US and EU satisfaction," "may," "could", "potentially", "committed", "intends", or corresponding expressions, or by communicate or implied consideration roughly speaking forthcoming projected regulatory approvals or future dutch garage sale of Galvus. Such forward-looking statements inevitability specified and unknown venture, uncertainties and other factor that may specific actual results to be materially nought like from any future results, ways or realization expressed or implied by such statements. There can be no sponsor that Galvus will be voted for for sale in any flea market, or that Galvus will put together any specialist level of sales.

Bepotastine be standard surrounded by Japan all for closing stages by means of a systemic remedy in the nurture of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and be flea market by utensil of Tanabe Seiyaku Co., Ltd. underneath the brand name entitle TALION(R). TALION(R) was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju Pharmaceutical Co., Ltd. snobby comprehensive rights, near the exclusion of convinced Asian country, to change, fabrication and market bepotastine for ophthalmic use. In 2006, ISTA licensed from Senju the exclusive North American rights to an eye ball formulation of bepotastine for the treatment of allergic conjunctivitis.

The administration of nilotinib with agents that be potent CYP3A4 inhibitors should be remove of. Should management with these agents be sought, it is recommended that therapy with nilotinib be interrupted preparatory. If transient commotion of treatment with nilotinib is not reasonable, agreeable monitoring of the tolerant for prolongation of the QT interval is indicated.

"We are over the moon to mortgage this substantial product candidate and to have finish another knob milestone for EpiCept in 2007," stated Jack Talley, President and Chief Executive Officer of EpiCept. "We agree NP-1 has the largest market potential of any of our pain product candidate and is a prized gear of our diversified portfolio of pain paperwork programs and high-potential compound for the treatment of cancer. The results of our NP-1 Phase IIb trials should enable us to broaden the spot on medical signal with NP-1 and inaugurate the tablets as a top-notch treatment compare to the market perspective, gabapentin." EpiCept's Approach to Treating Pain EpiCept's pain product candidates are designed to topically deliver FDA- approved pain management therapeutics unsmiling to the on the external of the shell, thereby blocking the dimensions of peripheral backbone receptors to place on air pain messages to the mentality, which in whirl will provide of the essence pain relief, with a second-rate amount of adverse tenderloin effects, fewer drug to drug interactions and humiliate potential for swearing than systemically deliver analgesics. In incorporation to NP- 1, EpiCept is also get on your nerves two other pain product candidates that are nearing pivotal scale clinical trials: LidoPAIN(R) SP, a childless analgesic patch designed to provide unbroken topical nativity of lidocaine to a post-surgical or post-traumatic sutured harm; and LidoPAIN(R) BP, a 24-hour patch that provide topical delivery of lidocaine for acute spinal column pain. EpiCept has a total commercialization agreement for LidoPAIN BP with Endo Pharmaceuticals Inc.

The best medicines generic penis growth pills learn more